Andrea F. Wainer - Dec 13, 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Dec 13, 2021
Transactions value $
-$1,340,500
Form type
4
Date filed
12/15/2021, 05:38 PM
Previous filing
Dec 8, 2021
Next filing
Dec 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $329K +7K +14.06% $47.00 56.8K Dec 13, 2021 Direct
transaction ABT Common shares without par value Options Exercise $288K +7.5K +13.21% $38.40 64.3K Dec 13, 2021 Direct
transaction ABT Common shares without par value Sale -$1.96M -14.5K -22.56% $135.00 49.8K Dec 13, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -7K -24.37% $0.00 21.7K Dec 13, 2021 Common Shares 7K $47.00 Direct F1
transaction ABT Option (right to buy) Options Exercise $0 -7.5K -33.33% $0.00 15K Dec 13, 2021 Common Shares 7.5K $38.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).